| Title |
Current advances in biomarkers for targeted therapy in triple-negative breast cancer
|
|---|---|
| Published in |
Breast cancer targets and therapy, October 2016
|
| DOI | 10.2147/bctt.s114659 |
| Pubmed ID | |
| Authors |
Brett Fleisher, Charlotte Clarke, Sihem Ait-Oudhia |
| Abstract |
Triple-negative breast cancer (TNBC) is a complex heterogeneous disease characterized by the absence of three hallmark receptors: human epidermal growth factor receptor 2, estrogen receptor, and progesterone receptor. Compared to other breast cancer subtypes, TNBC is more aggressive, has a higher prevalence in African-Americans, and more frequently affects younger patients. Currently, TNBC lacks clinically accepted targets for tailored therapy, warranting the need for candidate biomarkers. BiomarkerBase, an online platform used to find biomarkers reported in clinical trials, was utilized to screen all potential biomarkers for TNBC and select only the ones registered in completed TNBC trials through clinicaltrials.gov. The selected candidate biomarkers were classified as surrogate, prognostic, predictive, or pharmacodynamic (PD) and organized by location in the blood, on the cell surface, in the cytoplasm, or in the nucleus. Blood biomarkers include vascular endothelial growth factor/vascular endothelial growth factor receptor and interleukin-8 (IL-8); cell surface biomarkers include EGFR, insulin-like growth factor binding protein, c-Kit, c-Met, and PD-L1; cytoplasm biomarkers include PIK3CA, pAKT/S6/p4E-BP1, PTEN, ALDH1, and the PIK3CA/AKT/mTOR-related metabolites; and nucleus biomarkers include BRCA1, the gluco-corticoid receptor, TP53, and Ki67. Candidate biomarkers were further organized into a "cellular protein network" that demonstrates potential connectivity. This review provides an inventory and reference point for promising biomarkers for breakthrough targeted therapies in TNBC. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Greece | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Scientists | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 118 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 118 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 19 | 16% |
| Student > Bachelor | 18 | 15% |
| Student > Master | 17 | 14% |
| Researcher | 14 | 12% |
| Student > Doctoral Student | 5 | 4% |
| Other | 22 | 19% |
| Unknown | 23 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 32 | 27% |
| Biochemistry, Genetics and Molecular Biology | 25 | 21% |
| Agricultural and Biological Sciences | 15 | 13% |
| Computer Science | 4 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 3% |
| Other | 12 | 10% |
| Unknown | 26 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 April 2022.
All research outputs
#7,047,002
of 25,371,288 outputs
Outputs from Breast cancer targets and therapy
#89
of 324 outputs
Outputs of similar age
#100,728
of 332,555 outputs
Outputs of similar age from Breast cancer targets and therapy
#4
of 4 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 324 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one has gotten more attention than average, scoring higher than 71% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 332,555 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one.